Month: July 2022
-
DRC’s Take: Vertex to Acquire Chief T1D Stem Cell Competitor in All-Cash Deal
Vertex, whose VX-880 stem cell therapy for type 1 diabetes has cleared clinical proof of concept, is acquiring ViaCyte, a private biotech that has also reached clinical trials with its […]